The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.50
Bid: 26.00
Ask: 27.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.846%)
Open: 26.50
High: 26.50
Low: 26.50
Prev. Close: 26.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Renalytix Plc

21 Mar 2024 06:45

Form 8.5 (EPT/RI) - Renalytix Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix plc
(d) Date dealing undertaken: 20th March 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid / received (pence)Lowest price per unit paid / received (pence)
Ordinary Shares Sales 18,811 36.5 35.35

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
 

Date of disclosure:21st March 2024
Contact name:Rich White
Telephone number:+44 207 597 5462

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 202111:05 amRNSSecond Price Monitoring Extn
22nd Apr 202111:00 amRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNS10-year US Government contract award
20th Apr 20217:00 amRNSPositive clinical outcome data for KidneyIntelX
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.
7th Dec 20203:45 pmRNSResult of AGM
2nd Dec 20201:08 pmRNSPartnership with National Kidney Foundation
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:35 pmRNSPrice Monitoring Extension
25th Nov 20207:00 amRNSFinancial Results for First Quarter of FY 2021
13th Nov 20207:00 amRNSStifel 2020 Healthcare Conference
6th Nov 20207:00 amRNSChange of Adviser
2nd Nov 20203:30 pmRNSPosting of Annual Report & Accounts &Notice of AGM
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering
13th Jul 202012:01 pmRNSLaunch of Global Offering and application to list
13th Jul 202011:45 amRNSResult of General Meeting
8th Jul 20207:01 amRNSApproval of distribution of shares in Verici Dx

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.